Jonas Lundkvist

Summary

Country: Sweden

Publications

  1. ncbi request reprint Health economic evaluations alongside clinical trials: a review of study protocols at the Swedish Medical Products Agency
    Anne Lindfors
    Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
    Int J Technol Assess Health Care 23:392-6. 2007
  2. ncbi request reprint Proton therapy of cancer: potential clinical advantages and cost-effectiveness
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Acta Oncol 44:850-61. 2005
  3. ncbi request reprint Economic evaluation of proton radiation therapy in the treatment of breast cancer
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Radiother Oncol 75:179-85. 2005
  4. ncbi request reprint Cost of hypoglycemia in patients with Type 2 diabetes in Sweden
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Value Health 9:193-8. 2006
  5. ncbi request reprint Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma
    Jonas Lundkvist
    Medical Management Center, Karolinska Institutet, Stockholm, Sweden
    Cancer 103:793-801. 2005
  6. ncbi request reprint Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Stockholm Health Economics, Vasagatan 38, 111 20, Stockholm, Sweden
    Breast Cancer Res Treat 102:289-99. 2007
  7. doi request reprint Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
    Frida Kasteng
    i3 Innovus, Stockholm, Sweden
    Acta Oncol 47:1029-36. 2008
  8. ncbi request reprint The costs and benefits of regulations for reimbursement of new drugs
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Health Policy 79:337-44. 2006
  9. ncbi request reprint Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
    Jonas Lundkvist
    European Health Economics, Vasagatan 38, Stockholm, Sweden
    Eur J Health Econ 8:313-23. 2007
  10. ncbi request reprint Cost-effectiveness of new drugs: a systematic review of published evidence for new chemical entity drugs introduced on the Swedish market 1987-2000
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Int J Technol Assess Health Care 21:187-93. 2005

Detail Information

Publications20

  1. ncbi request reprint Health economic evaluations alongside clinical trials: a review of study protocols at the Swedish Medical Products Agency
    Anne Lindfors
    Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
    Int J Technol Assess Health Care 23:392-6. 2007
    ..This study examines the prevalence and study design of health economic evaluations conducted alongside clinical trials in Sweden between 1995 and 2005...
  2. ncbi request reprint Proton therapy of cancer: potential clinical advantages and cost-effectiveness
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Acta Oncol 44:850-61. 2005
    ..8 million. Investment in a proton facility may thus be cost-effective. The results must be interpreted with caution, since there is a lack of data, and consequently large uncertainties in the assumptions used...
  3. ncbi request reprint Economic evaluation of proton radiation therapy in the treatment of breast cancer
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Radiother Oncol 75:179-85. 2005
    ..It is therefore important to evaluate whether the medical benefits of proton therapy are large enough to justify the higher treatment costs, compared with conventional radiation therapy...
  4. ncbi request reprint Cost of hypoglycemia in patients with Type 2 diabetes in Sweden
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Value Health 9:193-8. 2006
    ..The cost of hypoglycemia is, however, not well identified, particularly in patients with Type 2 diabetes. The purpose of this study was to assess the cost of hypoglycemia in Type 2 diabetes in Sweden...
  5. ncbi request reprint Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma
    Jonas Lundkvist
    Medical Management Center, Karolinska Institutet, Stockholm, Sweden
    Cancer 103:793-801. 2005
    ..The objective of the current study was to assess the cost-effectiveness of proton therapy compared with conventional radiation therapy in the treatment of childhood medulloblastoma...
  6. ncbi request reprint Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Stockholm Health Economics, Vasagatan 38, 111 20, Stockholm, Sweden
    Breast Cancer Res Treat 102:289-99. 2007
    ....
  7. doi request reprint Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
    Frida Kasteng
    i3 Innovus, Stockholm, Sweden
    Acta Oncol 47:1029-36. 2008
    ..An economic evaluation was carried out to assess the cost-effectiveness in Sweden of rituximab as maintenance therapy for patients with follicular lymphoma in remission after second line therapy...
  8. ncbi request reprint The costs and benefits of regulations for reimbursement of new drugs
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Health Policy 79:337-44. 2006
    ..One potential cost is a delayed introduction of drugs on the market. The objective of this study was to discuss and analyse the time lag between drug authorisation and reimbursement for new chemical entities (NCEs) in Sweden and Finland...
  9. ncbi request reprint Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
    Jonas Lundkvist
    European Health Economics, Vasagatan 38, Stockholm, Sweden
    Eur J Health Econ 8:313-23. 2007
    ....
  10. ncbi request reprint Cost-effectiveness of new drugs: a systematic review of published evidence for new chemical entity drugs introduced on the Swedish market 1987-2000
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Int J Technol Assess Health Care 21:187-93. 2005
    ..The objective of this study was to analyze the amount of cost-effectiveness evidence for new drugs, by systematically reviewing the published evidence of cost-effectiveness...
  11. doi request reprint Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea
    Jonas Lundkvist
    i3innovus, Stockholm, Sweden
    J Travel Med 16:28-34. 2009
    ....
  12. ncbi request reprint The economic and quality of life impact of hypoglycemia
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Health Econ 6:197-202. 2005
    ..9 and $14.1, respectively, for a 1-month period. The results indicate that hypoglycemia is common, and that a reduction in these symptoms, without reducing glycemic control, may improve patient well-being and possibly also reduce cost...
  13. ncbi request reprint Pharmacoeconomics of adverse drug reactions
    Jonas Lundkvist
    Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
    Fundam Clin Pharmacol 18:275-80. 2004
    ..The problem with ADRs is, from an economic point of view, not a problem of minimization but of optimization, to find the right balance between costs and benefits...
  14. doi request reprint Similar cost for elective open and endovascular AAA repair in a population-based setting
    Kevin Mani
    Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University Hospital, Uppsala, Sweden
    J Endovasc Ther 15:1-11. 2008
    ..To compare cost differences between elective open repair (OR) and endovascular repair (EVAR) of abdominal aortic aneurysm in a population-based setting...
  15. ncbi request reprint Economic evaluations of leukemia: a review of the literature
    Frida Kasteng
    European Health Economics, Vasagatan 38, Stockholm 111 20, Sweden
    Int J Technol Assess Health Care 23:43-53. 2007
    ..More information about the total costs, that is, including indirect costs, and quality of life effects would be valuable in future evaluations in leukemia...
  16. ncbi request reprint [Economic evaluations more and more important in healthcare decision making. Costs must be balanced against benefits also in studies on health economics]
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institutet, Stockholm
    Lakartidningen 103:3624-7. 2006
  17. ncbi request reprint Cost-effectiveness of screening women for abdominal aortic aneurysm
    Anders Wanhainen
    Department of Surgery, Uppsala University Hospital, Uppsala, Sweden
    J Vasc Surg 43:908-14; discussion 914. 2006
    ..This position may, however, be questioned given the higher risk of rupture and the longer life expectancy among women. The purpose of this study was to assess the cost-effectiveness of screening 65-year-old women for AAA...
  18. ncbi request reprint Cost-effectiveness of different screening strategies for abdominal aortic aneurysm
    Anders Wanhainen
    Department of Surgery, Uppsala University Hospital, SE 371 85 Uppsala, Sweden
    J Vasc Surg 41:741-51; discussion 751. 2005
    ..The primary objective of this study was to develop a simulation model to assess the cost-effectiveness of different screening strategies for abdominal aortic aneurysms (AAAs) in men...
  19. ncbi request reprint Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
    Peter Aspelin
    Department of Radiology, Karolinska University Hospital, Huddinge, Sweden
    Am Heart J 149:298-303. 2005
    ..We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy...
  20. ncbi request reprint The more time spent on listening, the less time spent on prescribing antibiotics in general practice
    Jonas Lundkvist
    Department of Pharmaceutical Services Research, Uppsala University, Sweden
    Fam Pract 19:638-40. 2002
    ....